recombinant factor XIII

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Congenital Bleeding DisorderCongenital FXIII DeficiencyHealthy

Phase 1

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

CompletedNCT01082406

Novo Nordisk A/SCongenital Bleeding Disorder, Congenital FXIII Deficiency, Healthy

Start: 2010-03-31End: 2010-07-31Updated: 2016-09-21

Unknown Phase

A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

CompletedNCT02670213

Novo Nordisk A/SCongenital Bleeding Disorder, Congenital FXIII Deficiency

Start: 2016-03-16End: 2024-09-30Target: 8Updated: 2025-08-29